Cancer treatment with new drugs is lagging because NHS taked too long to approve them Cancer treatment is lagging in Britain because NHS watchdogs take too long to approve some of the best new drugs, experts have warned.
An increasing numbers of medicines have been licensed since 2000 to target new mutations in cancer.
But some are taking more than 20 years to reach NHS patients because regulators are 'too risk adverse', The Institute of Cancer Research said. The Daily Mail
See also:
An increasing numbers of medicines have been licensed since 2000 to target new mutations in cancer.
But some are taking more than 20 years to reach NHS patients because regulators are 'too risk adverse', The Institute of Cancer Research said. The Daily Mail
See also:
- Most innovative cancer drugs facing delays in reaching patients The Institute of Cancer Research
- Breakthrough cancer drugs take 22 years to reach the NHS The Daily Telegraph
No comments:
Post a Comment